{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:16:24Z","timestamp":1793992584959,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.drugalcdep.2013.12.019","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T15:46:22Z","timestamp":1389800782000},"page":"153-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Therapeutic infusions of ketamine: Do the psychoactive effects matter?"],"prefix":"10.1016","volume":"136","author":[{"given":"E.","family":"Dakwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Anerella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.R.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1037\/0022-3514.51.6.1173","article-title":"The moderator\u2013mediator variable distinction in social psychological research: conceptual, strategic and statistical considerations","volume":"51","author":"Baron","year":"1986","journal-title":"J. Pers. Soc. Psychol."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/jps.2600710516","article-title":"Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans","volume":"71","author":"Clements","year":"1982","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0015","article-title":"The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers","author":"Dakwar","year":"2013","journal-title":"Biol. Psych."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0899-3289(05)80057-4","article-title":"Stages of change profiles in outpatient alcoholism treatment","volume":"2","author":"DiClemente","year":"1990","journal-title":"J. Subst. Abuse"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0025","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0269881108094300","article-title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later","volume":"22","author":"Griffiths","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0035","series-title":"Psychedelics: The Uses and Implications of Hallucinogenic Drugs","first-page":"357","article-title":"Therapeutic uses","author":"Hoffer","year":"1970"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/1384454","article-title":"The construction and preliminary validation of a measure of reported mystical experience","volume":"14","author":"Hood","year":"1975","journal-title":"J. Sci. Study Relig."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0045","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/0021-8294.00085","article-title":"Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran","volume":"40","author":"Hood","year":"2001","journal-title":"J. Sci. Study Relig."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0050","series-title":"The Varieties of Religious Experience: A Study in Human Nature","author":"James","year":"1907"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0055","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0740-5472(02)00275-1","article-title":"Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up","volume":"23","author":"Krupitsky","year":"2002","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0070","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"20","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0075","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1037\/1064-1297.14.4.439","article-title":"Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults","volume":"14","author":"Lofwall","year":"2006","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0080","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","article-title":"Factor analysis of the Mystical Experience Questionnaire: a study of experiences occasioned by the hallucinogen psilocybin","volume":"51","author":"Maclean","year":"2012","journal-title":"J. Sci. Study Relig."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.biopsych.2007.05.028","article-title":"Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptors","volume":"63","author":"Maeng","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0090","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11599770-000000000-00000","article-title":"Ketamine for treatment-resistant unipolar depression: current evidence","volume":"26","author":"Mathew","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0095","series-title":"Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives","author":"Miller","year":"2001"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0100","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jclp.20000","article-title":"The phenomenon of quantum change","volume":"5","author":"Miller","year":"2004","journal-title":"J. Clin. Psychol."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00213-007-0706-2","article-title":"Psychiatric safety of ketamine in psychopharmacology research","volume":"192","author":"Perry","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0110","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1176\/appi.ajp.161.10.1776","article-title":"Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism","volume":"161","author":"Petrakis","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0115","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.biopsych.2009.04.029","article-title":"Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression","volume":"66","author":"Price","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.biopsych.2008.08.014","article-title":"Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine","volume":"65","author":"Salvadore","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0125","doi-asserted-by":"crossref","first-page":"e44799","DOI":"10.1371\/journal.pone.0044799","article-title":"Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action","volume":"7","author":"Scheidegger","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0130","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1081\/JA-100104085","article-title":"Measuring readiness for change among crack cocaine users: a descriptive analysis","volume":"36","author":"Siegal","year":"2001","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.tips.2009.09.002","article-title":"Glutamate-based antidepressants: 20 years on","volume":"30","author":"Skolnick","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0140","doi-asserted-by":"crossref","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0145","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0150","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nn1200","article-title":"Prefrontal responses to drug cues: a neurocognitive analysis","volume":"7","author":"Wilson","year":"2004","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.drugalcdep.2013.12.019_bib0160","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871613005358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871613005358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T05:26:18Z","timestamp":1538889978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871613005358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":32,"alternative-id":["S0376871613005358"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.12.019","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic infusions of ketamine: Do the psychoactive effects matter?","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}